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Stem cellDNA and histone chromatin modifying enzymes play a crucial role in chromatin remodeling in several biological
processes. Lysine-speciﬁc demethylase 1 (LSD1), the ﬁrst identiﬁed histone demethylase, is a relevant player in
the regulation of a broad spectrumof biological processes including development, cellular differentiation, embryonic
pluripotency and cancer. Here, we review recent insights on the role of LSD1 activity in chromatin regulatory
complexes, its functional role in the epigenetic changes during embryonic development, in the establishment and
maintenance of stemness and during cancer progression.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Epigenetic modiﬁcations are essential for normal development and
maintenance of tissue speciﬁc patterns of gene expression. Their herita-
bility is mediated by epigenetic modiﬁcations such as methylation of cy-
tosine in DNA, histone posttranslational modiﬁcations, and nucleosome
positioning along the DNA. Disruption of each one of these epigenetic
processes can lead to altered gene functions andmalignant cellular trans-
formation in cancers. Drastic changes in the cellular epigenetic proﬁle of
somatic cells occur during differentiation of cell identity,while disruption
of their epigenetic signatures by reprogramming factors may lead to the
acquisition of cell pluripotency [1–4].
Widespread epigenetic reprogramming occurs either during stem
cell differentiation and malignant transformation; genes involved in
differentiation programs are characterized by a poised transcriptional
statusmaintained by speciﬁc histonemethylationmarks typical of tran-
scriptional activation (H3K4me3) or repression (H3K27me3) at their
regulatory regions [3]. Among histone modiﬁcations, methylation and
its effects on gene expression are recently gaining popularity since it
was found that methylation marks are not static but dynamically regu-
lated by histone methyltransferases and histone demethylases [5,6].
Many studies have recently shed light on the role of the lysine speciﬁc
demethylase LSD1 (also known as KIAA061/KDM1/AOF2) in theerms of the Creative Commons
which permits non-commercial
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+39 081679233.
blished by Elsevier B.V. All rights remaintenance of the pluripotency in stem cells and in the oncogenic
gene programs that determine a block of cell differentiation [7–11].
The role of LSD1 in gene expression is emerging in the last few years be-
cause our understanding of epigenetic complexity and plasticity of ge-
nomes is exponentially growing up following the development of new
technologies that are providing comprehensive maps of localization of
histone modiﬁcations.
In this review we focus on the emerging evidences that correlate
LSD1 activity with epigenetic changes in the biology of stem and cancer
cells.
2. LSD1 structure and function
A protein homologous to FAD-dependent oxidoreductases, KIAA061
(LSD1) was found in the HDAC1 complexes [12] although the function
was not known at that time. Studies from Yang Shi's group reported
the identiﬁcation of KIAA061 (LSD1) in the CtBP complex [13] leading
to the discovery of the ﬁrst histone demethylase in 2004 [14]. Subse-
quent studies have shown histone demethylase activity for the closely
related KDM1B/AOF1/LSD2, as well as for orthologs in other species
[15–17].
LSD1 is a ﬂavin-containing amino oxidase (AO) that speciﬁcally cata-
lyzes the demethylation of mono- and di-methylated histone H3 lysine
4 [14,18–22] through a FAD-dependent oxidative reaction (Fig. 1A). In
this reaction, FAD oxidizes the methyl-lysine generating an imine inter-
mediate that is subsequently hydrolyzed to form unmodiﬁed lysine and
formaldehyde while the reduced FAD is re-oxidized by oxygen. LSD1
demethylates mono-/di-methylated lysines, but not tri-methylated ones
[14,18–22]. LSD1 is highly conserved and contains three protein domains:
an N-terminal SWIRM (Swi3p/Rsc8p/Moira) structural domain, a centralserved.
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Fig. 1. A. Schematic representation of the LSD1 protein. B. FAD-dependent demethylation of dimethylated lysine residues by LSD1. C. LSD1-associated complexes and their demethylation
targets.
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[22]. The SWIRM and AO domains interact to form a core structure that
binds FAD not covalently and serves as the enzymatic domain; the
tower domain provides a surface platform for interaction with partners
(Fig. 1B). Because of the strong structural andmechanistic similarities be-
tween LSD1 catalytic domain and conventional amine oxidases, mono-
amine oxidase (MAO) inhibitors as the tranylcypromine (TCP),
covalently bind FAD and inhibit LSD1 activity [23]. On the other hand,
pargyline, a propargylamine containing small molecule initially pro-
posed as LSD1 inhibitor, failed to appreciably inactivate LSD1 in subse-
quent studies [21,24,25]. A series of new tranylcypromine analogs
have been developed and biochemical and biological evaluation of
their inhibitory properties and efﬁcacy for human LSD1 and LSD2 has
been assayed [23–25]. Some of these compounds are effective LSD1 in-
hibitors, andmost importantly they exhibit in vivo efﬁcacy in tumors by
altering the chromatin state and synergistically cooperate with
antitumoral drugs [24,25].
The molecular mechanism underlying LSD1 transcriptional regula-
tion remains confuse, essentially because LSD1 associates with different
complexes and it can function as co-repressor or co-activator in a target-
speciﬁc manner. LSD1 has been found in different transcriptional
complexes involved in transcription repression such as CoREST and
NuRD (Fig. 1C) [13]. Consistent with its role in transcription repression,
LSD1 demethylates monomethyl and dimethyl histone H3 lysine 4
(H3K4me1 and H3K4me2), which are marks of active chromatin tran-
scription state.
LSD1 has also been found to have a role in transcriptional activation
as exempliﬁed by the nuclear hormone receptors induced transcription.
The interaction of LSD1 with androgen (AR) or estrogen (ER) nuclear
receptors seems to change its substrate speciﬁcity from H3K4me1/
me2 to H3K9me1/me2 [26–31];moreover, it has been recently reported
that, following hormone treatment, protein kinase C is recruited to ARtarget promoters and phosphorylates H3 threonine 6 (H3T6). This mod-
iﬁcation switches LSD1 H3K4 demethylating activity from H3K4me2 to
H3K9me1 and H3K9me2 [27]. Also, ER mediated demethylation of
H3K9 by LSD1 has been hypothesized to be due to H3K9 demethylase
associated with LSD1 or to a reader of H3 methylation that changes
LSD1 speciﬁcity [31]. As demethylation reaction by LSD1 release H2O2,
it has been proposed that LSD1 recruitment by ER and Myc on their
respective targets, triggers DNA oxidation and recruitment of base exci-
sion repair enzymes that favors chromatin looping for transcriptional
activation–repression [28,32,33]. More recently, LSD1 was found to be
part of protein complexes responsible for transcription elongation: the
ELL complex containing the P-TEFb transcriptional elongation factor
and the MLL super-complex containing both transcriptional activators
and repressors [34,35].
It is evident that association of LSD1 with speciﬁc partners deter-
mines its substrate speciﬁcity. Moreover, concomitant histone modiﬁ-
cations such as deacetylation or phosphorylation may inﬂuence LSD1
activity as H3K9 acetylation and/or H3S10 phosphorylation negatively
affect LSD1 H3K4 demethylase activity [11,21,24,26].
3. Non-histone LSD1 substrates
It has been found that LSD1 demethylates also non-histone proteins.
LSD1 speciﬁcally demethylates p53 dimethylated K370 residue, signiﬁ-
cantly altering its function [36,37], indeed, dimethylated but not mono-
methylated p53 can interact with its coactivator 53BP1. These studies
point to an active involvement of LSD1 in the DNA damage response
pathway, via direct modulation of p53 activity, and suggest that LSD1
may inhibit apoptosis. LSD1 also inhibits DNA damage-induced cell
death in the absence of p53 throughmodulation of the E2F protein stabil-
ity [38,39]. Demethylation of E2F1 in lysine185 inhibits other E2Fmodiﬁ-
cations that drive E2F degradation thus, favoring E2F accumulation
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sin phosphataseMYPT1, a phosphatase involved inRb dephosphorylation
[40]. MYPT1 demethylation enhances its ubiquitination and instability;
consequently, MYPT1 degradation enhances Rb phosphorylation and
may affect cell cycle consistent with high levels of LSD1 and low levels
of MYPT1 found in cancer.
Among the LSD1 substrates there is also Dnmt1 [41], the major
enzyme responsible formaintaining DNAmethylation during DNA repli-
cation. LSD1 knock out in mouse embryonic stem (ES) cells leads to de-
crease in Dnmt1 protein levels and a concomitant loss of global DNA
methylation. These studies revealed that LSD1, in addition to its direct
activity on chromatin structure, also regulates global or speciﬁc gene
expression patterns through demethylation of non-histone targets.
4. Developmental role of LSD1
Genetic studies in multiple model systems have shown that LSD1
is an important player in developmental processes [9]. In mice loss of
LSD1 causes embryonic lethality at approximately day 6 [41,42]. LSD1
expression is restricted to epiblast and LSD1-null mice embryos are
reduced in size compared to heterozygous controls suggesting a
block to development shortly after implantation [41,42]. Embryonic
lethality in these mice seems to occur for an aberrant developmental
program rather than impaired proliferation. LSD1 orthologs in
Drosophila melanogaster and Caenorhabdis elegans are expressed in the
germline, and the Drosophila LSD1 mutants have a germline-speciﬁc
phenotype [17,43,44]. Inactivation of the Drosophila LSD1, Su(var)3–3
(suppressor of variegation 3–3), a suppressor of heterochromatic silenc-
ing, leads to sterility and tissue defects. In these mutant animals changes
of global H3K4me2/me1 levels and reduction of H3K9me in heterochro-
matic regions have been observed. Data reported by the authors suggest
that H3K4me2 LSD1 demethylase activity indirectly affects H3K9me
levels. The C. elegans SPR-5 (suppressor of presenilin defect) protein has
also been implicated in the control of H3K4me2 levels in the germline.
Data reported by the authors suggest that H3K4me2 LSD1 demethylase
activity indirectly affects H3K9me levels. The C. elegans SPR-5 (suppressor
of presenilin defect) protein has also been implicated in the control of
H3K4me2 levels in the germline. Increased levels of H3K4me2 are only
observed in late generations, correlating with deregulation of genes
expressed in spermatogenesis and animal infertility. In summary, LSD1
is essential formouse development,while the LSD1orthologs inC. elegans
andDrosophila are important players in the germline. Collectively, studies
in different model systems suggest that perturbation of enzymes that
regulate H3K4me and H3K9me, such as LSD1, leads to defects in many
meiotic steps and it is essential for mouse development. In addition,
several reports strongly indicate that LSD1 is required for differentiation
of several cell types [45], such as adipogenesis [46], skeletalmuscle differ-
entiation [47] and it is involved in the epithelial-to-mesenchymal transi-
tion. Epithelial to mesenchymal transition, EMT, is a paradigm of cell
plasticity that it is characterized by reversible loss of epithelial character-
istics and acquisition ofmesenchymal properties. During EMT transition a
global H3K9me2 reduction and H3K4me3 and H3K36me3 increase have
been observed [48]. These changes have been found to be largely depen-
dent on LSD1 activity and loss of LSD1 function has marked effects on
EMT-driven cell migration and chemoresistance. In human cancer EMT
is largely due to Snail mediated repression of transcription of epithelial
genes and it has been shown that LSD1 functionally interacts with Snail
and it is recruited on epithelial gene promoters [49]. In summary, the
number of studies reporting a causative role of LSD1 in differentiation
process in several different cell systems is currently growing.
5. Stemness control by LSD1
The pluripotent state of embryonic stem cells (ESCs) is of great
interest as model system for studying the mechanisms controlling
“stemness” such as self-renewal and pluripotency. It has beenhypothesized that the similarities shared by stem and cancer cells
might be related to shared gene expression patterns. The acquisition
of pluripotency during the reprogrammingprocess is somehow reminis-
cent of the de-differentiation process resulting in cancers as proposed
[50]. Intriguingly, it has been shown that the signaling pathways in-
volved in the regulation of the biology of stem and cancer cells belong
to functionally separable modules (Core, Polycomb and Myc) [51–53].
The pluripotent state of ESC is maintained through the combinatorial
actions of core transcription factors, including Oct4, Sox2, and Nanog
[53,54], microRNAs [55], signaling pathways [56,57], and most impor-
tantly regulatory mechanisms involving epigenetic regulation.
Recently, several reports correlate LSD1 function to the control of
gene expression during ESC differentiation. It has been reported that
LDS1 knock out in mouse ESCs shows increased apoptosis, impaired
differentiation ability and, more importantly, failure to maintain the
global levels of DNA methylation [41]. The same group described a
mechanism that involves LSD1 in the regulation of Dnmt1. The
demethylase Dnmt1 is a LSD1 substrate that removes K1096 residue
of Dnmt1 resulting in the stabilization of the protein [41]. Thus,
LSD1 and KMTs (Set7/9 responsible for DnmT1 K1096 methylation)
dynamically regulate the methylation status of Dnmt1 having a crucial
role in development and differentiation through regulation of global
DNA methylation. In another study, conditional LSD1 knockout in
mouse ESCs does not affect their stem cell phenotype (i.e. expression
of Oct4, Nanog, and alkaline phosphatase) thus indicating that LSD1 is
not essential for the maintenance of ESC state [42]. ESC lacking LSD1
proliferate normally but show increased levels of cell death upon differ-
entiation. Loss of LSD1 activity results in the premature activation of
brachyury, a key regulator of mesoderm formation [42]. Additional
evidences that the loss of LSD1 causes a precocious expression of devel-
opmental markers have been provided by Adamo et al., in human ESC.
LSD1 knockdown by shRNA, in human ESC causes a decrease in growth
rate characterized by partial cell arrest in the G0/G1 phase [58,59] and
up-regulation of genes involved in the development processes such
as FOXA2 (forkhead box A2), EOMES (eomesodermin), BMP2 (bone
morphogenetic protein 2) and SOX17. These data suggest that LSD1 is
essential to regulate balance between H3K4me2/me3 and H3K27me3
at target developmental genes that are poised in human ESC cells.
A study from Young's laboratory has recently provided further
insight on the role of LSD1 in ESC differentiation. Using chromatin im-
munoprecipitation coupled with massive parallel DNA sequencing
(ChIP-Seq), it has been shown that LSD1 occupies the enhancer and
core promoters of a signiﬁcant number of actively transcribed genes
and that the enzyme is required during differentiation for enhancer
silencing (enhancer decommissioning) of ESC speciﬁc genes mediated
by the NuRD complex [60]. Upon differentiation, LSD1 demethylates
H3K4me1 at the enhancer of ESC speciﬁc genes, thus determining
repression of Oct4/Sox/Nanog-regulated gene targets. A mechanistic
model for LSD1 function in ESC has been proposed. LSD1–NuRD com-
plex binds to Oct4-active enhancers in ESCs but it is unable to demeth-
ylate H3K4. Since LSD1 activity is inhibited in the presence of acetylated
histones [21,23], histone acetylation levels at enhancers co-occupied by
both HATs and NuRD associated HDACs suppress demethylase activity
of bound LSD1. During ESC differentiation, histone acetylation levels
at ESC genes decrease, thus allowing LSD1-dependent demethylase ac-
tivity, and then, gene silencing. These ﬁndings suggest a possible role of
LSD1 in normal differentiation of ESCs, when the active enhancersmust
be silenced, rather than in the maintenance of the ESC state [60].
6. Myc and LSD1 co-occupancy in ES cells
Myc family members are critical to maintain embryonic stem cells
(ESCs) in the undifferentiated state. Myc over expression can block dif-
ferentiation and cooperates with Oct3/4, Sox2 and Klf4 to reprogram
adult differentiated cells into induced pluripotent stem cells (iPS) that
resemble ESC cells [61,62]. Inmouse ESC,Myc regulates the transcription
984 S. Amente et al. / Biochimica et Biophysica Acta 1829 (2013) 981–986of all core components of the Polycomb repressive complex 2 (PRC2) by
binding to the E-box elements of PRC2 genes [63]. As discussed above,
ChIP-Seq data revealed that LSD1 occupies the enhancer/promoter
regions of actively transcribed genes in mouse ESCs [60]. Intriguingly, a
large fraction of Myc targets correlate with LSD1 and Pol II occupancy.
Fig. 2 shows Pol II, LSD1 and c-Myc binding to 5 Myc targets (Ncl,
Apex1, Ezh2, Eed, Suz12). The functional relevance of the co-occupancy
of Myc/LSD1/Pol II at Myc promoter targets in ES cells remains to be
addressed, taking into account that it has been shown that recruitment
ofMyc/LSD1 on promoters is a necessary and early event to initiate tran-
scription of Myc targets [32,33]. Chemical LSD1 inhibitors have been
successfully used to block the growth of ES cells as well as pluripotent
carcinomas as teratomas, embryonic carcinoma and seminoma [10];
and it is likely that the same chemical compounds can be used to dissect
the role of Myc–LSD1 in gene expression in ES cells.
7. LSD1 and cancer
Notwithstanding LSD1 has been reported to be associatedwith cancer
only few years ago and it has been found to possess oncogenic prop-
erties in several cancers ranging from prostate [64], bladder [65],
neuroblastomas [66], lung cancers [67] sarcomas and hepato-
carcinomas [68]. LSD1 inhibition reduces or blocks cell growth in
many of these tumors, while its over-expression has been found to
contribute to human carcinogenesis through chromatinmodiﬁcation
[69].
7.1. LSD1 and acute myeloid leukemia
During the last year two different groups pointed out the role of
LSD1 in leukemia and provided preclinical proof of concept for using
LSD1 pharmacological inhibitors to treat acute leukemia [70,71].
Acute leukemias are clonal disorders of hematopoiesis in which
leukemic stem cells (LSCs) develop unlimited self-renewal capacity,
enhanced proliferation and impaired hematopoietic differentiation
programs. Recent advances in leukemia biology come from studiesAPEX1 EZHNCL
Pol2
LSD1
c-Myc
Fig. 2. An adapted UCSC Genome browser view displaying Pol II LSD1 and Myc binding on 5
Pol2, GSE12680; LSD1, GSE27844; and c-Myc, GSE11431.that investigated on genetic and epigenetic abnormalities in leukemic
cells [72].
Leukemic stem cells (LSCs) are a functionally deﬁned multipotent
entity that can undergo self-renewal, the origin of which has been the
subject of considerable research in recent years. During normal devel-
opmental progression from stem cell to progenitors and then mature
cells, mutations may potentially occur at any stage giving rise to a
malignant entity. The role of LSD1 as essential regulator of LSC potential
has been described in a mouse and human models of human MLL-AF9
leukemia [73]. The extent of LSD1 knockdown signiﬁcantly correlated
with loss of the LSC potential of AML cells through impairment of differ-
entiation and apoptosis. Cells without active LSD1 are unable to form col-
onies (consistent with loss of LSC potential) exhibit differentiated cell
morphology and are not able to cause leukemia when introduced into
mice [70]. The causative role of LSD1 over-expression in AML leukemia
has been substantiated by the concomitant results obtained in a cytoge-
netically distinct subtype of AML, the acute promyelocytic leukemia,
APL, characterized by a translocation involving promyelocytic leukemia
gene, PML and the retinoic acid receptor, RARα genes. Therapy of this
leukemia with pharmacological concentrations of all-trans-retinoic-acid
(ATRA) promotes differentiation of leukemic cells, but someAPL subtypes
are resistant to ATRA. However, concomitant administration of ATRA and
a pharmacological inhibitor of LSD1 (tranylcypromine, TCP) induce mor-
phological and immunophenotypic differentiation of APML cells in vitro.
The ﬁndings that LSD1 has a major role in AML progression push the
efforts to understand the genetic program regulated by LSD1 [71]. LSD1
may contribute directly or indirectly to maintain expression of key tran-
scription factors and chromatin modifying enzymes. Expression analysis
suggests that LSD1 might regulate a subset of genes that activate the on-
cogenic program associated with MLL-AF9 leukemia and chromatin im-
munoprecipitation and next generation sequencing, (ChIP-Seq), showed
that H3K4me2 increase is the only detectable change at MLL-AF9 pro-
moters following LSD1 silencing. These results clearly demonstrate that
in AML, demethylation by LSD1 is associated with activation of LSC asso-
ciated oncogenic target genes [70]. Given the relevant ﬁndings regarding
the role of LSD1 in sustaining the oncogenic gene program and the block
of differentiation in MLL cells, the mechanisms by which LSD1 functions2 SUZ12EED
Myc targets in mouse ES cells. Raw ChIP-Seq data were from GEO accession numbers:
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loci require further investigations.
7.2. LSD1 and T cell leukemia
In T-cell acute lymphoblastic leukemia (T-ALL) resulting from the
malignant transformation of T-cell progenitors, mutations in Notch1,
leading to aberrant and constitutively active Notch1 signaling, contribute
to oncogenic transformation and are hallmarks of this disease
[74,75]. It has been recently found that LSD1 participates to a
Notch-containing multifunctional complex; furthermore, together
with the PFH8 demethylase it is involved in the epigeneticmodiﬁcation
of Notch1 target genes [75]. In T-ALL, Notch mediated regulation of its
targets is the ﬁrst example of the dual role of LSD1 as activator or re-
pressor; it is known that the DNA-binding factor CSL binds and re-
presses Notch targets in the absence of Notch, while the presence of
Notch converts CSL in a transcriptional activator. The ﬁnding that
LSD1 interacts with CSL explains the mechanism through which Notch
determines gene repression by removing the H3K4me2 marks at
Notch targets in the absence of Notch. Indeed, a functional switch of
LSD1 activity is observed upon Notch activation. In the absence of
Notch, LSD1 triggers H3K4me2 demethylation while in its presence
the enzyme acts preferentially on H3K9me2 leading to activation of tar-
get genes. Thus, LSD1 inhibition in T-ALL reproduces cell growth arrest
and alteration of growth, and a phenotype was previously attributed to
Notch silencing [75].
Huang's laboratory has shown that LSD1 is associatedwith the hema-
topoietic speciﬁc transcription factor TAL1/SCL whose disregulation has
been associated with T cell leukemogenesis. LSD1/Tal1 association is
disrupted by phosphorylation of serine 172 in TAL1 by protein-kinase-A
(PKA) and the destabilized TAL1–LSD1 interaction leads to promoter
H3K4 hypermethylation and activation of target genes [76,77]. Thus, a
PKA-dependent dynamic interaction between LSD1 and TAL1 has a caus-
ative role in hematopoiesis and leukemogenesis.
7.3. LSD1 and solid tumors
High levels of LSD1 protein have been found in several types of solid
tumors and are associated with poor prognosis. This is the reason why
LSD1 has been proposed as a biomarker for neuroblastoma, non-small
cell lung carcinomas (NSCLC), breast and prostate cancers [65–69]. In
NSCLC it has been shown that down regulation of LSD1 expression by
the pharmacological inhibitor pargyline or by speciﬁc siRNAs determines
suppression of cell growth, migration and invasion. Similarly, LSD1
immuno-reactivity is increased in a substantial fraction of hepato-
carcinomas, (HCC), and LSD1 knockdown in HCC cells decreases sub-
stantial cell proliferation [68].
8. Conclusion and future directions
LSD1 is promiscuously bound at multiple sites across the genome
predominantly at active promoters and enhancers. However, several
different LSD1-containing complexes have been described; it is likely
that the formation and stability of LSD1 complexes present on different
gene targets depend on the cellular context and environmental signals.
The major future challenge is the dissection of LSD1 epigenetic role
and the mechanism of formation of these inhibitory or stimulatory
LSD1 containing complexes. Further analysis to identify molecular sig-
naling affecting the nature and function of LSD1-complexes will im-
prove our knowledge of epigenetic modiﬁcations and their functional
outcome in cancer and stem cell differentiation and reprogramming.
Considering the association between high levels of LSD1 and neoplastic
progression, LSD1 has become an attracting target for drug discovery,
and it has been proposed that epigenetic drugs targeting LSD1 could
be therapeutically used alone or in combination with other therapeutic
tools. Recently, two reports have independently provided preclinicalproof of concept for using lysine-speciﬁc histone demethylase 1 inhibi-
tors to treat acute myelogenous leukemia [70,71]. The discovery and
development of ﬂexible and selective LSD1 inhibitors will undoubtedly
help our understanding of its role in epigenetic regulation of both in can-
cer and cell differentiation, andwill allow the development of molecular
therapies aimed to inhibit tumor growth and promote cell differentiation
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